1. Li S, Hu Y, Tan X, et al. Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes. Expert Opin Pharmacother. 2020;21(11):1311–8.
2. Thieu VT, Mitchell BD, Varnado OJ, et al. Treatment and prevention of severe hypoglycaemia in people with diabetes: current and new formulations of glucagon. Diabetes Obes Metab. 2020;22(4):469–79.
3. Zealand Pharma. ZEGALOGUE (dasiglucagon) injection, for subcutaneous use: US prescribing information. 2021. https://www.accessdata.fda.gov/. Accessed 28 Apr 2021.
4. Zealand Pharma. Zealand Pharma announces FDA approval of Zegalogue® (dasiglucagon) injection, for the treatment of severe hypoglycemia in people with diabetes [media release]. 2021. http://www.zealandpharma.com. Accessed 22 Mar 2021.
5. Zealand Pharma. Zealand Pharma initiates second phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism [media release]. 2019. http://www.zealandpharma.com. Accessed 4 Dec 2019.